Bevacizumab plus capecitabine is valid for the first-line treatment of patients with HER2-negative, locally recurrent, or metastatic breast cancer, according to the final results from a study published in The Lancet Oncology.1
For this international, open-label study, researchers enrolled 564 patients with measurable or non-measurable HER2-negative, locally recurrent, or metastatic breast cancer, each of whom did not receive prior chemotherapy for locally recurrent or metastatic disease.
Participants were randomly assigned 1:1 to receive bevacizumab 10 mg/kg on days 1 and 15 plus paclitaxel 90 mg/m2 on days 1, 8, and 15 every 4 weeks, or bevacizumab 15 mg/kg on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks until disease progression or unacceptable toxicity.
RELATED: Young Age Appears Prognostic for Women With Luminal Breast Cancers
Median overall survival was 30.2 months (95% CI, 25.6-32.6) for bevacizumab plus paclitaxel compared with 26.1 months (95% CI, 22.1-29.0) for bevacizumab plus capecitabine (hazard ratio, 1.02; P = .0070), indicating non-inferiority between the 2 regimens.
Serious adverse events were observed in 23% and 25% of patients in the bevacizumab plus paclitaxel arm and the bevacizumab plus capecitabine arm, respectively. Two patients in the bevacizumab plus paclitaxel group died from the treatment.
- Zielinski C, Lang I, Inbar M, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol. 2016 Aug 5. doi: 10.1016/S1470-2045(16)30154-1 [Epub ahead of print]